Final winter, inside days of the Supreme Courtroom’s determination to listen to Dobbs v. Jackson Ladies’s Well being Group, an abortion case that might intestine entry to reproductive care, the Meals and Drug Administration introduced that it will permit abortion medicine to be accessible by mail, with out an in-person docs’ go to.
The transfer was heralded as an answer to the prospect of diminished entry, although states are already gearing as much as curtail these drugs, too. The information, nonetheless, additionally illuminated simply how medicine may tackle a extra vital position in society, intersecting politics and private well being and selection in stunning new methods.
The March difficulty of the Spotlight was impressed by precisely this concept. With every of its tales, it asks, “Are medicine the reply?”
We take a look at not solely the telehealth startups aiming to offer pregnant individuals with abortion remedy underneath more and more draconian state legal guidelines, but additionally the comparatively newly accessible Covid-19 antiviral medicine and the position they must play in the way forward for the pandemic, if the federal government can get them to the individuals who want them most. Paxlovid and molnupiravir, the 2 therapeutic antivirals have proven various however promising ranges of effectiveness in stunting Covid-19’s risks. So, what position may these therapeutics have in spelling the tip of the pandemic? Might they work in tandem with vaccines, or maybe be an choice for individuals who is not going to take the vaccine or do not need entry to it?
We additionally study the development towards wider acceptance of once-illicit medicine corresponding to psilocybin (a.okay.a. mushrooms), LSD, and hashish throughout the wellness sphere. They’re marketed in more and more inoffensive methods, from gummies to candies to tiny mints, with only a few milligrams a dose, and a few are touting their capacity to deal with every thing from alcohol dependence to melancholy.
Lastly, our cowl story appears to be like at a query that has been effervescent for years amongst advocates, lawmakers, and activists: Why can’t the US determine one federal coverage to legalize marijuana? A number of years into states’ grand experiment to legalize and regulate hashish, we all know this a lot: The tax windfall may very well be big; it may swiftly reverse the criminalization of brown and Black People that has continued underneath the Drug Conflict; and it will open doorways to medical analysis, amongst many different advantages. Bipartisan help for federal legalization additionally means that medicine, within the case of hashish specifically, may very well be the reply. Overseeing a beforehand unregulated business underneath nationwide hashish coverage, nonetheless, is laced with extra inequity and stress than it might sound.
Maintain studying for extra:
The brand new, easy-to-take antivirals are actually on pharmacy cabinets. That is who they stand to assist essentially the most.
By Katherine Harmon Braveness
The FDA made mail-order abortion drugs authorized. Entry continues to be a nightmare. (Coming Tuesday)
Restrictive states have already set their sights on a brand new wave of telehealth corporations that have been alleged to be a panacea for a post-Roe world.
By Julia Craven
The brand new sober-ish (Coming Wednesday)
Tiny doses of magic mushrooms, LSD, and hashish have hit wellness tradition, whereas the stigma across the medicine recedes.
By Luke Winkie
Why can’t we determine one federal coverage to legalize marijuana? (Coming Thursday)
Public opinion, lawmakers, and states are aligned that it could be time to legalize hashish. So, how laborious is it to lastly get it completed?
By Mary Jane Gibson